Data was expressed by mean ± SD. CRP:C-reactive protein; SAA:Serum amyloid A; WBC:White blood cell; Hb:Hemoglobin; PLT:Blood platelet; IL-1β:Interleukin-1β; IL-2:Interleukin-2; IL-4:Interleukin-4; IL-5:Interleukin-5; IL-6:Interleukin-6; IL-8:Interleukin-8; IL-10:Interleukin-10; IL-12p70:Interleukin-12p70; IL-17A:Interleukin-17A; TNF-α:Tumor necrosis factor-alpha-α; NK cells:Natural killer cells;ALT: Alanine aminotransferase; AST: Aspartate amino transferase; LDH: Lactic dehydrogenase; ALP: Alkaline phosphatase; γ-GT: γ-glutamyl transferase; TBil: Total bilirubin; ChE:Cholinesterase; UA:Uric acid; TG:Triglyceride; TC: Total cholesterol; HDL-C: High-density lipoprotein cholesterol;LDL-C:Low-density lipoprotein cholesterol; non- HDL-C:Non-high-density lipoprotein cholesterol;HbA1c:Glycosylated hemoglobin A1C

Figure legend

Figure 1 Significant Changes in glycolipid immunometabolism parameters treated by Paxlovid among non-severe COVID-19 patients in Renji hospital.

Figure 2 Cox proportional hazards regression for days of viral elimination* and clinical glycolipid immunometabolism factors among non-severe COVID-19 patients in Renji hospital.

* Viral elimination was defined as both negative for ORF1ab and N genes (Ct value ≥35 by real-time PCR) in two consecutive days. The second negative day was calculated as the time point of viral elimination. CI: confidence interval; IL-6: Interleukin-6; IL-10: Interleukin-10; TG:Triglyceride; TC: Total cholesterol; HDL-C: High-density lipoprotein cholesterol;LDL-C:Low-density lipoprotein cholesterol; non- HDL-C:Non-high-density lipoprotein cholesterol;